Caspofungin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candidiasis, Esophageal
Conditions
Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
Trial Timeline
Jul 6, 2010 → Sep 17, 2013
NCT ID
NCT01165320About Caspofungin
Caspofungin is a phase 2 stage product being developed by Merck for Candidiasis, Esophageal. The current trial status is completed. This product is registered under clinical trial identifier NCT01165320. Target conditions include Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02596984 | Pre-clinical | Completed |
| NCT01499433 | Approved | UNKNOWN |
| NCT01318148 | Phase 2 | Completed |
| NCT01165320 | Phase 2 | Completed |
| NCT01260974 | Phase 2 | UNKNOWN |
| NCT00333645 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Candidiasis, Esophageal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 33 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 85 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 77 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 77 |
| micafungin + amphotericin B deoxycholate | Astellas Pharma | Phase 3 | 77 |
| FK463 | Astellas Pharma | Phase 2 | 52 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 77 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| L-743,872 | Merck | Pre-clinical | 23 |
| L-743,872 | Merck | Phase 2 | 52 |
| Caspofungin + Amphotericin B Deoxycholate | Merck | Phase 2 | 52 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 52 |
| Caspofungin + Normal Saline | Merck | Approved | 85 |
| caspofungin acetate | Merck | Phase 3 | 77 |